- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Navigating Unmet Needs in Dry Eye Disease Therapies
Richard Adler, MD, FACS, Assistant Professor of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins Institute, and Director of Ophthalmology Services at Belcara Health, discusses the critical unmet needs in Dry Eye Disease (DED) therapies and explores the potential impact of new agents in addressing these challenges.
EP: 1.Navigating Unmet Needs in Dry Eye Disease Therapies
EP: 2.Key Takeaways from Phase 4 Switch Trial Presented at AAO
EP: 3.Real World Benefit Related to Improving Corneal Staining
EP: 4.Overview of Phase 3 Perfluorohexyloctane Studies at AAO 2023
EP: 5.Updates from the SAHARA Trial at AAO 2023
EP: 6.Dual Mechanism Dry Eye Treatment Shows Promise for Symptoms and Compliance
This is a video synopsis/summary of a Post Conference Perspectives involving Richard Adler, MD.
There are many unmet needs in the treatment of dry eye disease (DED). Of the approximately 38 million Americans suffering from DED, only 17 million have received a diagnosis and just 1.1 million have been prescribed treatment. This compares to 4 million annual cataract surgeries and 3 million annual glaucoma diagnoses nationally. Successful dry eye treatments should aim to harmonize the frequently discordant signs and symptoms, address underlying inflammation and tear production issues, and improve patient quality of life. From a drug development perspective, ideal treatments would demonstrate rapid onset and durable symptom relief with improved delivery, bioavailability, and tolerability. Cyclosporine ophthalmic emulsion 0.05% (Restasis) was approved in 2002 but still has shortcomings after 20 years on the market, notably its poor water solubility given the aqueous environment of tears, leading to suboptimal drug delivery and tissue penetration. Innovations addressing these limitations by enhancing cyclosporine delivery and bioavailability remain unmet needs.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD
April 8th 2025Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.
Read More
Worse CTD-PAH Prognosis Seen With Higher HFA-PEFF Score
April 8th 2025The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) stratified by their Heart Failure Association–preserved ejection fraction (HFA-PEFF) algorithm score.
Read More
Guselkumab Shows Sustained Efficacy in Phase 3b APEX Study for Active PsA
April 8th 2025Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting structural damage in patients with active psoriatic arthritis (PsA).
Read More
